CN1283258C - Medicine for preventing fibrous liver and preparing method thereof - Google Patents
Medicine for preventing fibrous liver and preparing method thereof Download PDFInfo
- Publication number
- CN1283258C CN1283258C CN 03119759 CN03119759A CN1283258C CN 1283258 C CN1283258 C CN 1283258C CN 03119759 CN03119759 CN 03119759 CN 03119759 A CN03119759 A CN 03119759A CN 1283258 C CN1283258 C CN 1283258C
- Authority
- CN
- China
- Prior art keywords
- extract
- salviae miltiorrhizae
- paeoniae rubra
- filtrate
- radix paeoniae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 9
- 229940079593 drug Drugs 0.000 title claims description 37
- 210000004185 liver Anatomy 0.000 title description 5
- 239000000284 extract Substances 0.000 claims abstract description 95
- 206010019668 Hepatic fibrosis Diseases 0.000 claims abstract description 49
- 239000002775 capsule Substances 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 59
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- 239000000706 filtrate Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000011347 resin Substances 0.000 claims description 17
- 229920005989 resin Polymers 0.000 claims description 17
- 108010010803 Gelatin Proteins 0.000 claims description 15
- 229920000159 gelatin Polymers 0.000 claims description 15
- 239000008273 gelatin Substances 0.000 claims description 15
- 235000019322 gelatine Nutrition 0.000 claims description 15
- 235000011852 gelatine desserts Nutrition 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 11
- 239000003480 eluent Substances 0.000 claims description 10
- 238000001291 vacuum drying Methods 0.000 claims description 10
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 claims description 6
- 241001072909 Salvia Species 0.000 claims description 6
- 235000017276 Salvia Nutrition 0.000 claims description 6
- IUKLSMSEHKDIIP-BZMYINFQSA-N Verticine Chemical compound C([C@@H]1[C@@H](O)C[C@H]2[C@@H]3CC[C@@H]4[C@]5(C)O)[C@@H](O)CC[C@]1(C)[C@H]2C[C@H]3[C@@H]4CN1[C@H]5CC[C@H](C)C1 IUKLSMSEHKDIIP-BZMYINFQSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- IUKLSMSEHKDIIP-UHFFFAOYSA-N petine Natural products CC1(O)C2CCC3C4CC(O)C5CC(O)CCC5(C)C4CC3C2CN2C1CCC(C)C2 IUKLSMSEHKDIIP-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 235000018553 tannin Nutrition 0.000 claims description 5
- 229920001864 tannin Polymers 0.000 claims description 5
- 239000001648 tannin Substances 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000008120 corn starch Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 150000002989 phenols Chemical class 0.000 claims description 3
- 229960003371 protocatechualdehyde Drugs 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 3
- 239000007963 capsule composition Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 241000736199 Paeonia Species 0.000 abstract description 4
- 239000008187 granular material Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 3
- 240000007164 Salvia officinalis Species 0.000 abstract 3
- 235000005412 red sage Nutrition 0.000 abstract 3
- 239000000470 constituent Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- PZTQVMXMKVTIRC-UHFFFAOYSA-L chembl2028348 Chemical compound [Ca+2].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 PZTQVMXMKVTIRC-UHFFFAOYSA-L 0.000 description 13
- 230000000694 effects Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 229960003160 hyaluronic acid Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical group C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 241000205571 Caulophyllum Species 0.000 description 1
- 241000189665 Colchicum autumnale Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine for treating hepatic fibrosis, particularly to a medicine for preventing hepatic fibrosis, which is prepared from red sage root extract and red peony root extract. The medicine for preventing hepatic fibrosis can be made into various oral dosage forms, such as tablets, granules, powder, capsules, oral liquid, etc. The medicine for preventing hepatic fibrosis is a medicament which is made from the following constituents of the shares by weight: 2 to 8 shares of red sage root extract, 2 to 8 shares of red peony root extract, and the preferred share proportion is that the red sage root extract: the red peony root extract is 7: 3. The present invention also provides a method for preparing a medicine for preventing hepatic fibrosis.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of hepatic fibrosis, particularly use the medicine that Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract prepare anti-hepatic fibrosis.
Background technology
Hepatic fibrosis is that hepatocyte necroses or during inflammatory stimulus, the paraplasm pathological change process of fibrous connective tissue in the liver, and various chronic hepatopathys such as viral hepatitis, alcoholic liver disease etc. all can develop into hepatic fibrosis, liver cirrhosis.Hepatitis is one of China's sickness rate disease with high, it is reported, hepatitis accounts for more than 10% of total population at the sickness rate of China.China is again the big country of drinking in the world, adds the change of environmental pollution and dietary structure, and at present, the sickness rate of hepatic fibrosis is in continuous rising, has now become one of problem that China hygiene department is concerned about, payes attention to most.In recent years, Chinese scholars has proposed a series of anti-hepatic fibrosis medicines and method to the formation mechanism of hepatic fibrosis, as the application corticoid, and treatments such as interferon, but the curative effect of these medicines can not be affirmed.Though have the treatment of Colchicum autumnale aspect anti-hepatic fibrosis to obtain certainly, it has bigger toxic and side effects, be difficult for taking for a long time.Chinese herbal medicine and preparation thereof are one of problems of domestic and international medical research unit primary study to the effect of anti-hepatic fibrosis always.In the recent period, China has begun to occur relevant compound recipe anti-hepatic fibrosis Chinese medicine preparation, as sunflower board liver-protecting tablet etc., but it is the big compound recipe crude preparation by using of Chinese medicine, and it is big to have a dose, and the cycle of taking is long, uncertain therapeutic efficacy is cut, treatment mechanism is difficult to shortcomings such as research, is difficult to deal with market anti-hepatic fibrosis patient's needs, more can't integrate with countries in the world.
Salviamiltiorrhizabung and Radix Paeoniae Rubra have certain blood circulation promoting and blood stasis dispelling, microcirculation improvement, increase liver blood flow amount, protect hepatocyte, alleviate hepatocellular degeneration, necrosis and inflammatory reaction, promote liver cell regeneration, suppress proliferation of fibrous tissue, suppress the hepatocyte lipid peroxidation, remove oxygen-derived free radicals, suppress collagenation and increase effect such as its decomposition.
The effective site Radix Salviae Miltiorrhizae extract of salviamiltiorrhizabung, it is the powder of being processed into through extraction separation by the dry root and rhizome of Labiatae Radix Salviae Miltiorrhizae (Salvia miltorrhiza Bunge), be the xanchromatic amorphous powder of a kind of palm fibre, gas is special, sour in the mouth, easily molten in water, methanol, ethanol, ethyl acetate.
Chinese medicine Radix Paeoniae Rubra is the dry rhizome of cohosh Radix Paeoniae (Paeonia lactflora Pall), the effective site Radix Paeoniae Rubra extract of Radix Paeoniae Rubra (Chishao Tiquwu) is processed into through extraction separation by the dry rhizome of Radix Paeoniae, be a kind of pale brown toner end, bitter in the mouth, easily molten in water, methanol, ethanol, ethyl acetate, insoluble in petroleum ether.
Utilize Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract to make the medicine of anti-hepatic fibrosis, yet there are no report.
Summary of the invention
The purpose of this invention is to provide medicine of a kind of anti-hepatic fibrosis and preparation method thereof.
Technical scheme of the present invention is: a kind of medicine of anti-hepatic fibrosis, mainly make: 8～2 parts of Radix Salviae Miltiorrhizae extracts, 2～8 parts of Radix Paeoniae Rubra extracts by following weight portion proportioning component; Described Radix Salviae Miltiorrhizae extract prepares according to following method: get salvia piece, decocting boils secondary, filters respectively, merge twice filtrate, be concentrated into every milliliter of filtrate and contain crude drug 1.0g, add 5% gelatin precipitation tannin in the filtrate after concentrating, placed 12 hours, and filtered, filtrate is concentrated into every milliliter and contains crude drug 1.5g, transfer pH2～3, reuse equal-volume ethyl acetate extraction three times merges ethyl acetate, the reclaim under reduced pressure ethyl acetate, through 80 ℃ of vacuum dryings, promptly get Radix Salviae Miltiorrhizae extract; Described Radix Paeoniae Rubra extract prepares in accordance with the following methods: get the Radix Paeoniae Rubra coarse powder, cross 20 mesh sieves, with 50% alcohol reflux secondary, the extracting solution that merges secondary, filter, reduce pressure back and get ethanol, concentrated filtrate to relative density is 1.10, adds triplication hot water dilution in concentrated solution, puts to add 5% gelatin water liquid after cold, making gelatin water liquid measure is 15% of former concentrated solution weight, place 24 hours after-filtration, filtrate is negative with deionized water rinsing reducing sugar reaction to the eluent by macroporous resin, reuse 40% ethanol elution, the eluent consumption is the 6BV of resin volume, the desorbing flow velocity is resin volume 1000.5-1BV/ hour, reduces pressure back and gets ethanol, and concentrate eluant to relative density is 1.30～1.35 thick extractum, through 80 ℃ of following vacuum dryings, promptly make Radix Paeoniae Rubra extract again.
Preferred version is 7 parts of described Radix Salviae Miltiorrhizae extracts, 3 parts of described Radix Paeoniae Rubra extracts.
Medicine of the present invention can add various pharmaceutically acceptable carriers.
Medicine of the present invention can be various peroral dosage forms, as various ways such as tablet, granule, powder, capsule, oral liquids.
When described anti-hepatic fibrosis medicines is capsule formulation, make by following component: Radix Salviae Miltiorrhizae extract 77g, Radix Paeoniae Rubra extract 33g, adjuvant 140g makes 1000 of capsules altogether.
Described adjuvant is microcrystalline cellulose or corn starch or hydroxymethyl starch.
The preparation method of anti-hepatic fibrosis medicines of the present invention comprises the steps:
A, the preparation of Radix Salviae Miltiorrhizae extract: get salvia piece, decocting boils secondary, add for the first time 10 times of amounts of water, add for the second time 6 times of amounts of water, twice decoction each 1.5 hours filters respectively, discards medicinal residues, merge twice filtrate then, be concentrated into every milliliter of filtrate and contain crude drug 1.0g, add 5% gelatin precipitation tannin in the filtrate after concentrating, placed 12 hours, filter, filtrate is concentrated into every milliliter and contains crude drug 1.5g, transfers pH2～3 with dilute hydrochloric acid, reuse equal-volume ethyl acetate extraction three times, merge ethyl acetate, the reclaim under reduced pressure ethyl acetate through 80 ℃ of vacuum dryings, promptly gets Radix Salviae Miltiorrhizae extract then, contain radix salviae miltiorrhizae peimine in the Radix Salviae Miltiorrhizae extract and must not calculate with radix salviae miltiorrhizae peimine sodium and be less than 10%, contain the salvia-soluble total phenols and must not calculate with protocatechualdehyde and be less than 60%;
B, the preparation of Radix Paeoniae Rubra extract: get Radix Paeoniae Rubra and be ground into coarse powder, cross 20 mesh sieves, with 50% alcohol reflux secondary, reflux, extract, is measured ethanol with 10 times for the first time, reflux, extract, is measured ethanol with 6 times for the second time, each 1.5 hours, the extracting solution that merges secondary filters, and reduces pressure back and gets ethanol, the relative density of concentrated filtrate to 60 ℃ is 1.10 then, add the hot water dilution of triplication≤90 ℃ in concentrated solution, put and add 5% gelatin water liquid after cold, making gelatin water liquid measure is 15% of former concentrated solution weight, place after 24 hours, filter, then that filtrate is negative with deionized water rinsing reducing sugar reaction to the eluent by macroporous resin, reuse 40% ethanol elution, the eluent consumption is the 6BV of resin volume, the desorbing flow velocity is resin volume 1000.5-1BV/ hour, reduces pressure back once more and gets ethanol, and the relative density of concentrate eluant to 50 ℃ is 1.30～1.35 thick extractum then, through 80 ℃ of following vacuum dryings, promptly make Radix Paeoniae Rubra extract again;
C, Radix Salviae Miltiorrhizae extract and the capsular preparation of Radix Paeoniae Rubra extract anti-hepatic fibrosis medicines: get Radix Salviae Miltiorrhizae extract 8～2 weight portions, Radix Paeoniae Rubra extract 2～8 weight portions add adjuvant, mixing sieves, with 80% ethanol wet granulation, incapsulate after the drying, promptly get the anti-hepatic fibrosis medicines capsule.
The medicine that Radix Salviae Miltiorrhizae extract provided by the present invention and Radix Paeoniae Rubra extract prepare anti-hepatic fibrosis proves through pharmaceutical research and drug effect animal experiment result of study: the related activity position of the effective component extracts of salviamiltiorrhizabung and Radix Paeoniae Rubra, proportioning by a certain percentage, picked-up and the decomposition of liver be can obviously increase, glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT rising suppressed hyaluronic acid, laminin; The same demonstration of animal pathological section has good preventive and therapeutic effect to hepatic fibrosis.Influence result of the test shown in table 1,2,3, Radix Salviae Miltiorrhizae extract to what cause tentative rat liver fibrosis with carbon tetrachloride: the anti-hepatic fibrosis medicines of Radix Paeoniae Rubra extract=7: 3 has than remarkable influence hyaluronic acid (HA), laminin (LN); Radix Salviae Miltiorrhizae extract: the anti-hepatic fibrosis medicines of Radix Paeoniae Rubra extract=5: 5 or 3: 7 has significant difference to glutamic oxaloacetic transaminase, GOT (AST); The Radix Salviae Miltiorrhizae extract of each dosage and Radix Paeoniae Rubra extract anti-hepatic fibrosis medicines test group have appreciable impact to glutamate pyruvate transaminase (ALT) and hepatic tissue hydroxyproline, zoopery shows that hepatic fibrosis has good preventive and therapeutic effect to experimental rat for Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract anti-hepatic fibrosis medicines.
Table 1: Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract anti-hepatic fibrosis medicines
The influence that the experimental rat liver function is detected (X ± SE)
| Group | n | Ancient pyruvic transaminase (ALT) | Ancient careless transaminase (AST) | Globulin (TP) | Albumin (ALB) |
| Normal group | 8 | 61.65±15.24 * | 159.84±37.14 * | 62.94±4.00 * | 27.06±2.10 * |
| Model group | 9 | 124.32±78.50 | 293.29±132.00 | 61.33±3.36 | 28.40±2.69 |
| The colchicine group | 8 | 50.58±8.30 * | 202.06±57.78 | 65.66±2.97 | 26.34±1.52 |
| Red 7: red 3 organize greatly | 8 | 57.39±12.95 * | 227.79±44.59 | 70,55±5.27 | 32.64±2.72 |
| Red 7: red 3 groups | 9 | 57.18±13.53 * | 245.58±53.98 | 64.10±5.59 | 29.77±2.44 |
| Red 5: red 5 organize greatly | 8 | 50.28±10.54 * | 163.51±38.61 * | 65.10±4.00 | 29.79±2.10 |
| Red 5: red 5 groups | 8 | 45.10±15.14 * | 119.06±31.29 * | 60.58±5.52 | 26.29±2.91 |
| Red 3: red 7 organize greatly | 8 | 44.00±15.04 * | 114.21±15.20 * | 64.53±7.71 | 28.53± |
| Red 3: red 7 groups | 9 | 53.73±14.76 * | 152.23±27.13 * | 63.64±5.96 | 28.22±3.11 |
Compare with model group:
*P＜0.05
Table 2: Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract anti-hepatic fibrosis medicines
To the influence of experimental rat hepatic fibrosis index of correlation (X ± SE)
| Group | n | Hyaluronic acid (HA) ng/ml | Laminin (LN) ug/l | Liver hydroxyproline ug/mgprot |
| Normal group | 8 | 79.91±18.68 * | 16.77±7.37 * | 1.35±0.29 * |
| Model group | 9 | 155.14±57.12 | 29.92±12.20 | 2.56±0.70 |
| The colchicine group | 8 | 97.27±23.98 * | 16.06±10.68 * | 1.61±0.40 * |
| Red 7: red 3 organize greatly | 8 | 96.14±33.34 * | 15.73±6.33(#) * | 1.73±0.37 * |
| Red 7: red 3 groups | 9 | 94.50±32.48 * | 6.69±2.01(#) * | 1.83±0.56 * |
| Red 5: red 5 organize greatly | 8 | 92.05±31.40 * | 3.21±0.79(#) * | 1.78±0.70 * |
| Red 5: red 5 groups | 8 | 102.08±28.31 * | 8.96±4.19(#) * | 1.87±0.35 * |
| Red 3: red 7 organize greatly | 8 | 111.99±37.87 | 17.93±9.46 | 1.85±0.61 * |
| Red 3: red 7 groups | 9 | 93.40±27.55 * | 11.87±6.96 * | 1.99±0.48 |
Compare with model group:
*P＜0.05
Table 3: Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract anti-hepatic fibrosis medicines
To experimental rat pathological observation result
| Group | Hepatic fibrosis | ||||||
| 0 grade | 1 grade | 2 grades | 3 grades | 4 grades | 5 grades | 6 grades | |
| Normal group | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Model group | 0 | 1 | 2 | 4 | 1 | 1 | 0 |
| The colchicine group | 0 | 4 | 7 | 1 | 0 | 0 | 0 |
| Red 7: red 3 organize greatly | 2 | 2 | 7 | 0 | 0 | 0 | 0 |
| Red 7: red 3 groups | 3 | 6 | 3 | 0 | 0 | 0 | 0 |
| Red 5: red 5 organize greatly | 1 | 2 | 7 | 0 | 0 | 0 | 0 |
| Red 5: red 5 groups | 1 | 0 | 9 | 1 | 0 | 0 | 0 |
| Red 3: red 7 organize greatly | 0 | 3 | 7 | 1 | 0 | 0 | 0 |
| Red 3: red 7 groups | 1 | 2 | 7 | 0 | 0 | 0 | 0 |
Learn check by statistics:
Model group: normal group x
2=11.22＞x
20.001 there is the difference of highly significant (1) P＜0.001 between model group and the normal group, show the modeling success.
Colchicine group: model group x
2=6.115＞x
20.05 (1) P＜0.05
Red red 73 organize greatly: model group x
2=6.960＞x
20.01 (1) P＜0.01
Red red 73 organize greatly: model group x
2=10.433＞x
20.01 (1) P＜0.01
Red red 55 organize greatly: model group x
2=6.110＞x
20.05 (1) P＜0.05
Red red 55 organize greatly: model group x
2=4.763＞x
20.05 (1) P＜0.05
Red red 37 organize greatly: model group x
2=4.287＞x
20.05 (1) P＜0.05
Red red 37 organize greatly: model group x
2=6.110＞x
20.05 (1) P＜0.05
This shows that each organizes medication therapy groups and Liver Fibrosis Model group, and all there were significant differences, illustrates that each dose compatibility of Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract all has the positive therapeutic effect to hepatic fibrosis.Wherein no matter red 7: red 3 big small dose group is from pathological section itself or statistical testing of business cycles, and curative effect is all more obvious.
The present invention shows through acute toxicity animal experiment result of study, the medicine of the anti-hepatic fibrosis of Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract preparation, and administration in selected dosage range has no side effect.
The invention has the advantages that: adopt effective ingredient in Chinese Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract to research and develop out the novel drugs of treatment hepatic fibrosis, hepatic fibrosis had good preventive and therapeutic effect and effect, be an extremely promising new Chinese medicine, have positive meaning safeguarding people ' s health.
Specific embodiment
The preparation of embodiment 1, Radix Salviae Miltiorrhizae extract
(1) preparation of salvia miltiorrhiza raw material and pre-treatment:
Get the salviamiltiorrhizabung that the place of production is Luoyang, Henan, require to meet pertinent regulations under Radix Salviae Miltiorrhizae item of Chinese Pharmacopoeia version in 2000.After medical material is selected, gets clean medical material 50Kg and thinly slice, standby.
(2) preparation technology:
Get salvia piece 50Kg, decocting boils secondary, adds doubly amount of water 10 (weight) for the first time, adds doubly amount of water 6 (weight) for the second time, and twice decoction each 1.5 hours filters respectively, discards medicinal residues, merges twice filtrate then, is concentrated into every milliliter of filtrate and contains crude drug 1.0g.Add 5% gelatin precipitation tannin in the filtrate after concentrating, placed 12 hours, filter, filtrate is concentrated into every milliliter and contains crude drug 1.5g, transfers PH2～3 with dilute hydrochloric acid, reuse equal-volume ethyl acetate extraction three times, merge ethyl acetate, the reclaim under reduced pressure ethyl acetate through 80 ℃ of vacuum dryings, promptly gets Radix Salviae Miltiorrhizae extract 1.285Kg then.This product contains radix salviae miltiorrhizae peimine and is calculated as 12.52% with radix salviae miltiorrhizae peimine sodium; Contain the salvia-soluble total phenols and be calculated as 82.79% with protocatechualdehyde.
The preparation of embodiment 2, Radix Paeoniae Rubra extract
(1) preparation of Radix Paeoniae Rubra raw material and pre-treatment:
Getting the place of production is the Chinese medicine Radix Paeoniae Rubra of Chifeng, the Inner Mongol, requires to meet pertinent regulations under Radix Paeoniae Rubra item of Chinese Pharmacopoeia version in 2000.Pulverizing Radix Paeoniae Rubra becomes coarse powder 25Kg standby.
(2) concrete preparation technology:
Get Radix Paeoniae Rubra coarse powder 25Kg, cross 20 mesh sieves, with 50% alcohol reflux secondary, reflux, extract, is measured ethanol with 10 times for the first time, reflux, extract, is measured ethanol with 6 times for the second time, each 1.5 hours, the extracting solution of merging secondary filtered, reduce pressure back and get ethanol, concentrated filtrate to relative density is 1.10 (60 ℃) then, adds hot water (≤90 ℃) dilution of triplication in concentrated solution, puts to add 5% gelatin water liquid after cold, making gelatin water liquid measure is 15% (w/w) of former concentrated solution, place after 24 hours, filter when reaching below 10 ℃, (the post reducing was than 24: 1 by ZTC-1 type macroporous resin with filtrate then; Medical material is 4: 1 with the resin demand ratio; The absorption flow velocity is resin volume 2-3BV/ hour) negative with deionized water rinsing reducing sugar reaction to the eluent, reuse 40% ethanol elution, the eluent consumption is the 6BV of resin volume, the desorbing flow velocity is resin volume 1000.5-1BV/ hour, reduce pressure back once more and get ethanol, concentrate eluant to relative density is the thick extractum of 1.30～1.35 (50 ℃) then, through 80 ℃ of following vacuum dryings, promptly makes Radix Paeoniae Rubra extract 0.962Kg again.This product contains peoniflorin 54.26%; Contain the Radix Paeoniae Rubra phenolic acid and be calculated as 8.39% with gallic acid.
Embodiment 3, Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract prepare the anti-hepatic fibrosis medicines capsule
(1) prescription:
Radix Salviae Miltiorrhizae extract 77g
Radix Paeoniae Rubra extract 33g
Microcrystalline cellulose 140g
Make 1000 of capsules altogether.
(2) preparation method:
Above-mentioned prescription raw material blending is sieved,, incapsulate after the drying and get final product with 80% ethanol wet granulation.
Embodiment 4, Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract prepare the anti-hepatic fibrosis medicines capsule
(1) prescription:
Radix Salviae Miltiorrhizae extract 55g
Radix Paeoniae Rubra extract 55g
Corn starch 140g
Make 1000 of capsules altogether.
(2) preparation method: with embodiment 3.
Embodiment 5, Radix Salviae Miltiorrhizae extract and Radix Paeoniae Rubra extract prepare the anti-hepatic fibrosis medicines capsule
(1) prescription:
Radix Salviae Miltiorrhizae extract 33g
Radix Paeoniae Rubra extract 77g
Hydroxymethyl starch 140g
Make 1000 of capsules altogether.
(2) preparation method: with embodiment 3.
Claims (6)
1, a kind of medicine of anti-hepatic fibrosis is mainly made by following weight portion proportioning component: 8～2 parts of Radix Salviae Miltiorrhizae extracts, 2～8 parts of Radix Paeoniae Rubra extracts;
Described Radix Salviae Miltiorrhizae extract prepares according to following method: get salvia piece, decocting boils secondary, filters respectively, merge twice filtrate, be concentrated into every milliliter of filtrate and contain crude drug 1.0g, add 5% gelatin precipitation tannin in the filtrate after concentrating, placed 12 hours, and filtered, filtrate is concentrated into every milliliter and contains crude drug 1.5g, transfer pH2～3, reuse equal-volume ethyl acetate extraction three times merges ethyl acetate, the reclaim under reduced pressure ethyl acetate, through 80 ℃ of vacuum dryings, promptly get Radix Salviae Miltiorrhizae extract;
Described Radix Paeoniae Rubra extract prepares in accordance with the following methods: get the Radix Paeoniae Rubra coarse powder, cross 20 mesh sieves, with 50% alcohol reflux secondary, the extracting solution that merges secondary, filter, reduce pressure back and get ethanol, concentrated filtrate to relative density is 1.10, adds triplication hot water dilution in concentrated solution, puts to add 5% gelatin water liquid after cold, making gelatin water liquid measure is 15% of former concentrated solution weight, place 24 hours after-filtration, filtrate is negative with deionized water rinsing reducing sugar reaction to the eluent by macroporous resin, reuse 40% ethanol elution, the eluent consumption is the 6BV of resin volume, the desorbing flow velocity is resin volume 1000.5-1BV/ hour, reduces pressure back and gets ethanol, and concentrate eluant to relative density is 1.30～1.35 thick extractum, through 80 ℃ of following vacuum dryings, promptly make Radix Paeoniae Rubra extract again.
2, medicine according to claim 1 is characterized in that 7 parts of described Radix Salviae Miltiorrhizae extracts, 3 parts of described Radix Paeoniae Rubra extracts.
3, medicine according to claim 1 and 2 is characterized in that described anti-hepatic fibrosis medicines is a peroral dosage form.
4, medicine according to claim 1 and 2 is characterized in that described anti-hepatic fibrosis medicines is a capsule formulation, is made by following component: Radix Salviae Miltiorrhizae extract 77g, and Radix Paeoniae Rubra extract 33g, adjuvant 140g makes 1000 of capsules altogether.
5, medicine according to claim 4 is characterized in that described adjuvant is microcrystalline cellulose or corn starch or hydroxymethyl starch.
6, prepare the method for the described anti-hepatic fibrosis medicines of claim 4, comprise the steps:
A, the preparation of Radix Salviae Miltiorrhizae extract: get salvia piece, decocting boils secondary, add for the first time 10 times of amounts of water, add for the second time 6 times of amounts of water, twice decoction each 1.5 hours filters respectively, discards medicinal residues, merge twice filtrate then, be concentrated into every milliliter of filtrate and contain crude drug 1.0g, add 5% gelatin precipitation tannin in the filtrate after concentrating, placed 12 hours, filter, filtrate is concentrated into every milliliter and contains crude drug 1.5g, transfers pH2～3 with dilute hydrochloric acid, reuse equal-volume ethyl acetate extraction three times, merge ethyl acetate, the reclaim under reduced pressure ethyl acetate through 80 ℃ of vacuum dryings, promptly gets Radix Salviae Miltiorrhizae extract then, contain radix salviae miltiorrhizae peimine in the Radix Salviae Miltiorrhizae extract and must not calculate with radix salviae miltiorrhizae peimine sodium and be less than 10%, contain the salvia-soluble total phenols and must not calculate with protocatechualdehyde and be less than 60%;
B, the preparation of Radix Paeoniae Rubra extract: get Radix Paeoniae Rubra and be ground into coarse powder, cross 20 mesh sieves, with 50% alcohol reflux secondary, reflux, extract, is measured ethanol with 10 times for the first time, reflux, extract, is measured ethanol with 6 times for the second time, each 1.5 hours, the extracting solution that merges secondary filters, and reduces pressure back and gets ethanol, the relative density of concentrated filtrate to 60 ℃ is 1.10 then, add the hot water dilution of triplication≤90 ℃ in concentrated solution, put and add 5% gelatin water liquid after cold, making gelatin water liquid measure is 15% of former concentrated solution weight, place after 24 hours, filter, then that filtrate is negative with deionized water rinsing reducing sugar reaction to the eluent by macroporous resin, reuse 40% ethanol elution, the eluent consumption is the 6BV of resin volume, the desorbing flow velocity is resin volume 1000.5-1BV/ hour, reduces pressure back once more and gets ethanol, and the relative density of concentrate eluant to 50 ℃ is 1.30～1.35 thick extractum then, through 80 ℃ of following vacuum dryings, promptly make Radix Paeoniae Rubra extract again;
C, Radix Salviae Miltiorrhizae extract and the capsular preparation of Radix Paeoniae Rubra extract anti-hepatic fibrosis medicines: get Radix Salviae Miltiorrhizae extract 8～2 weight portions, Radix Paeoniae Rubra extract 2～8 weight portions add adjuvant, mixing sieves, with 80% ethanol wet granulation, incapsulate after the drying, promptly get the anti-hepatic fibrosis medicines capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03119759 CN1283258C (en) | 2003-03-11 | 2003-03-11 | Medicine for preventing fibrous liver and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03119759 CN1283258C (en) | 2003-03-11 | 2003-03-11 | Medicine for preventing fibrous liver and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1530112A CN1530112A (en) | 2004-09-22 |
| CN1283258C true CN1283258C (en) | 2006-11-08 |
Family
ID=34285251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03119759 Expired - Fee Related CN1283258C (en) | 2003-03-11 | 2003-03-11 | Medicine for preventing fibrous liver and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1283258C (en) |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8776633B2 (en) | 2006-01-30 | 2014-07-15 | Fallbrook Intellectual Property Company Llc | System for manipulating a continuously variable transmission |
| US8818661B2 (en) | 2008-08-05 | 2014-08-26 | Fallbrook Intellectual Property Company Llc | Methods for control of transmission and prime mover |
| US8845485B2 (en) | 2011-04-04 | 2014-09-30 | Fallbrook Intellectual Property Company Llc | Auxiliary power unit having a continuously variable transmission |
| US8852050B2 (en) | 2008-08-26 | 2014-10-07 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US8870711B2 (en) | 2008-10-14 | 2014-10-28 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US8888643B2 (en) | 2010-11-10 | 2014-11-18 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US8900085B2 (en) | 2007-07-05 | 2014-12-02 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US8920285B2 (en) | 2004-10-05 | 2014-12-30 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US8996263B2 (en) | 2007-11-16 | 2015-03-31 | Fallbrook Intellectual Property Company Llc | Controller for variable transmission |
| US9017207B2 (en) | 2006-06-26 | 2015-04-28 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US9022889B2 (en) | 2005-10-28 | 2015-05-05 | Fallbrook Intellectual Property Company Llc | Electromotive drives |
| US9046158B2 (en) | 2003-02-28 | 2015-06-02 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US9074674B2 (en) | 2008-06-23 | 2015-07-07 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US9086145B2 (en) | 2006-11-08 | 2015-07-21 | Fallbrook Intellectual Property Company Llc | Clamping force generator |
| US9121464B2 (en) | 2005-12-09 | 2015-09-01 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US9182018B2 (en) | 2008-02-29 | 2015-11-10 | Fallbrook Intellectual Property Company Llc | Continuously and/or infinitely variable transmissions and methods therefor |
| US9239099B2 (en) | 2007-02-16 | 2016-01-19 | Fallbrook Intellectual Property Company Llc | Infinitely variable transmissions, continuously variable transmissions, methods, assemblies, subassemblies, and components therefor |
| US9249880B2 (en) | 2007-12-21 | 2016-02-02 | Fallbrook Intellectual Property Company Llc | Automatic transmissions and methods therefor |
| US9273760B2 (en) | 2007-04-24 | 2016-03-01 | Fallbrook Intellectual Property Company Llc | Electric traction drives |
| US9279482B2 (en) | 2009-04-16 | 2016-03-08 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US9328807B2 (en) | 2007-02-01 | 2016-05-03 | Fallbrook Intellectual Property Company Llc | Systems and methods for control of transmission and/or prime mover |
| US9341246B2 (en) | 2005-11-22 | 2016-05-17 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US9360089B2 (en) | 2010-03-03 | 2016-06-07 | Fallbrook Intellectual Property Company Llc | Infinitely variable transmissions, continuously variable transmissions, methods, assemblies, subassemblies, and components therefor |
| US9371894B2 (en) | 2007-02-12 | 2016-06-21 | Fallbrook Intellectual Property Company Llc | Continuously variable transmissions and methods therefor |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103191186A (en) * | 2012-01-04 | 2013-07-10 | 天士力制药集团股份有限公司 | Application of salvia miltiorrhiza preparation in preparing anti-liver-fibrosis medicines |
| CN104800776A (en) * | 2015-05-19 | 2015-07-29 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating alcoholic hepatic fibrosis |
| CN111419912B (en) * | 2020-03-21 | 2022-05-13 | 北京中医药大学 | Red peony root polyphenol pharmaceutical preparation for treating acute hepatitis and preparation method thereof |
-
2003
- 2003-03-11 CN CN 03119759 patent/CN1283258C/en not_active Expired - Fee Related
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9046158B2 (en) | 2003-02-28 | 2015-06-02 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US8920285B2 (en) | 2004-10-05 | 2014-12-30 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US9506562B2 (en) | 2005-10-28 | 2016-11-29 | Fallbrook Intellectual Property Company Llc | Electromotive drives |
| US9022889B2 (en) | 2005-10-28 | 2015-05-05 | Fallbrook Intellectual Property Company Llc | Electromotive drives |
| US9341246B2 (en) | 2005-11-22 | 2016-05-17 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US9121464B2 (en) | 2005-12-09 | 2015-09-01 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US8776633B2 (en) | 2006-01-30 | 2014-07-15 | Fallbrook Intellectual Property Company Llc | System for manipulating a continuously variable transmission |
| US9017207B2 (en) | 2006-06-26 | 2015-04-28 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US9086145B2 (en) | 2006-11-08 | 2015-07-21 | Fallbrook Intellectual Property Company Llc | Clamping force generator |
| US9328807B2 (en) | 2007-02-01 | 2016-05-03 | Fallbrook Intellectual Property Company Llc | Systems and methods for control of transmission and/or prime mover |
| US9371894B2 (en) | 2007-02-12 | 2016-06-21 | Fallbrook Intellectual Property Company Llc | Continuously variable transmissions and methods therefor |
| US9239099B2 (en) | 2007-02-16 | 2016-01-19 | Fallbrook Intellectual Property Company Llc | Infinitely variable transmissions, continuously variable transmissions, methods, assemblies, subassemblies, and components therefor |
| US9273760B2 (en) | 2007-04-24 | 2016-03-01 | Fallbrook Intellectual Property Company Llc | Electric traction drives |
| US9574643B2 (en) | 2007-04-24 | 2017-02-21 | Fallbrook Intellectual Property Company Llc | Electric traction drives |
| US8900085B2 (en) | 2007-07-05 | 2014-12-02 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US8996263B2 (en) | 2007-11-16 | 2015-03-31 | Fallbrook Intellectual Property Company Llc | Controller for variable transmission |
| US9249880B2 (en) | 2007-12-21 | 2016-02-02 | Fallbrook Intellectual Property Company Llc | Automatic transmissions and methods therefor |
| US9182018B2 (en) | 2008-02-29 | 2015-11-10 | Fallbrook Intellectual Property Company Llc | Continuously and/or infinitely variable transmissions and methods therefor |
| US9074674B2 (en) | 2008-06-23 | 2015-07-07 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US9528561B2 (en) | 2008-06-23 | 2016-12-27 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US9365203B2 (en) | 2008-08-05 | 2016-06-14 | Fallbrook Intellectual Property Company Llc | Systems and methods for control of transmission and/or prime mover |
| US8818661B2 (en) | 2008-08-05 | 2014-08-26 | Fallbrook Intellectual Property Company Llc | Methods for control of transmission and prime mover |
| US8852050B2 (en) | 2008-08-26 | 2014-10-07 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US8870711B2 (en) | 2008-10-14 | 2014-10-28 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US9574642B2 (en) | 2008-10-14 | 2017-02-21 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US9279482B2 (en) | 2009-04-16 | 2016-03-08 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US9360089B2 (en) | 2010-03-03 | 2016-06-07 | Fallbrook Intellectual Property Company Llc | Infinitely variable transmissions, continuously variable transmissions, methods, assemblies, subassemblies, and components therefor |
| US9291251B2 (en) | 2010-11-10 | 2016-03-22 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US8888643B2 (en) | 2010-11-10 | 2014-11-18 | Fallbrook Intellectual Property Company Llc | Continuously variable transmission |
| US8845485B2 (en) | 2011-04-04 | 2014-09-30 | Fallbrook Intellectual Property Company Llc | Auxiliary power unit having a continuously variable transmission |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1530112A (en) | 2004-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1283258C (en) | Medicine for preventing fibrous liver and preparing method thereof | |
| CN1413724A (en) | Brain active substance for preventing and treating encephalopathy and improving intelligence and preparation method thereof | |
| CN101933991B (en) | Analgesic and anti-inflammatory medicine and preparation method thereof | |
| CN104547826B (en) | Galangal rhizome extract treats the medical usage of dysmenorrhoea | |
| CN1243743A (en) | Medicine for treating chronic hepatism and its preparing process | |
| CN100534508C (en) | Method for extracting effective sites group of smilax China root | |
| CN1839944A (en) | Granular composition for reducing blood fat and process for producing the same | |
| CN100427136C (en) | A kind of pharmaceutical composition for treating fatty liver and its preparation method and application | |
| CN1611232A (en) | Medicinal composition with main effect of antifatigue, radioresistance and melancholia-resistance and its preparing method | |
| CN101385783A (en) | Huganning tablets for treating chronic and urgent liver disease and preparation method thereof | |
| CN1216613C (en) | Health-care product capable of regulating blood-lipid and its preparation method | |
| CN1218697C (en) | Pharmaceutical composition and dietary supplement for treating or improving arthritis | |
| CN1272054C (en) | Medicine for treating diabetes and its preparing process | |
| CN112843202A (en) | Traditional Chinese medicine composition with anti-depression effect and preparation method and application thereof | |
| CN1234409C (en) | Combinaton of medication for treating depression and preparation method | |
| CN1927324A (en) | Preparation method of traditional medicine preparation for treating women's menoxenia | |
| CN1672722A (en) | A kind of heart-nourishing and tranquilizing medicine and preparation method thereof | |
| CN1470271A (en) | Chinese medicinal compound preparation for treating liver fibrillation disease and its preparation method | |
| CN114129675B (en) | A kind of traditional Chinese medicine composition and its application | |
| CN103919972B (en) | A kind of pharmaceutical composition of resisting fatigue and its preparation method and application | |
| CN1660282A (en) | Combination of medication for treating hepatitis B and preparation method | |
| CN1973857A (en) | Chinese medicine red sage-astragalus root prepn for treating liver fibrosis and liver cirrhosis and its prepn process | |
| CN1730090A (en) | Chinese traditional medicinal composition for treating hepatitis and process for preparing the same | |
| CN1650943A (en) | A drug for treating hypertension | |
| CN1204916C (en) | Medicine for treating depression and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING INTERNATIONAL BIOLOGY PRODUCTS INSTITUTE Free format text: FORMER OWNER: JINQIAO SHIDAI BIOMEDICAL RESEARCH DEVELOPMENT CENTER, BEIJING Effective date: 20070316 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20070316 Address after: 100086 No. 42, Zhongguancun Avenue, Haidian District, Beijing Patentee after: Beijing International Biological Products Research Institute Co Ltd Address before: 100086 No. 42, Zhongguancun Avenue, Haidian District, Beijing Patentee before: Jinqiao Shidai Biological Medicine Research and Development Center, Beijing |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061108 Termination date: 20180311 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |